Recent Food and Drug Administration Decisions and the Future of the Development of Cancer Drugs in the US

This Viewpoint discusses recent US Food and Drug Administration (FDA) decisions regarding oncology drug trials for refractory melanoma and their potential negative impacts on the US regulatory environment.

Authors

Institutions

Publication Details

Journal
JAMA Oncology
Published
2026-08-20
DOI
https://doi.org/10.1001/jamaoncol.2026.2843
Primary Topic
Melanoma and MAPK Pathways
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Recent Food and Drug Administration Decisions and the Future of the Development of Cancer Drugs in the US

Gilberto Lopes
JAMA Oncology
Melanoma and MAPK Pathways
article

Recent Food and Drug Administration Decisions and the Future of the Development of Cancer Drugs in the US

Gilberto Lopes
article en

Abstract

This Viewpoint discusses recent US Food and Drug Administration (FDA) decisions regarding oncology drug trials for refractory melanoma and their potential negative impacts on the US regulatory environment.

JAMA Oncology
University of Miami (US), Sylvester Comprehensive Cancer Center (US)
Good health and well-being
Openalex Percentile: Top 16%
Melanoma and MAPK Pathways
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Recent Food and Drug Administration Decisions and the Future of the Development of Cancer Drugs in the US — Gilberto Lopes · JAMA Oncology (2026) | TGRS Research Map | TGRS